Compare DG & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DG | INSM |
|---|---|---|
| Founded | 1939 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2B | 22.4B |
| IPO Year | 2008 | 2000 |
| Metric | DG | INSM |
|---|---|---|
| Price | $130.97 | $125.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 24 |
| Target Price | $139.60 | ★ $201.17 |
| AVG Volume (30 Days) | 2.0M | ★ 2.6M |
| Earning Date | 06-02-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.07% | N/A |
| EPS Growth | ★ 34.05 | N/A |
| EPS | ★ 4.49 | N/A |
| Revenue | ★ $42,724,369,000.00 | N/A |
| Revenue This Year | $7.14 | $182.31 |
| Revenue Next Year | $4.17 | $65.19 |
| P/E Ratio | $29.16 | ★ N/A |
| Revenue Growth | ★ 5.20 | N/A |
| 52 Week Low | $95.11 | $90.39 |
| 52 Week High | $158.23 | $212.75 |
| Indicator | DG | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 62.88 | 56.41 |
| Support Level | $115.31 | $122.21 |
| Resistance Level | $132.31 | $137.70 |
| Average True Range (ATR) | 3.86 | 3.90 |
| MACD | 0.85 | -0.74 |
| Stochastic Oscillator | 83.84 | 59.50 |
Since its beginning in 1939, Dollar General has grown to become the largest dollar store operator in the United States, with more than 20,000 small-box discount stores across 48 states. The firm generated over $42 billion in fiscal 2025 sales. The retailer maintains a heavy concentration of stores in rural and low-income markets underserved by big-box retailers. It's 11,000 stock-keeping units, including 2,000 priced at $1 or less, span consumables (82% of sales), seasonal items (10%), home products (5%), and apparel (3%). More than 20% of sales are derived from private label.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.